20 June 2013
Keywords: ra, golimumab, patients, see, das28, remissions, findings
Article | 23 June 2008
Findings from two new Phase III studies showed that patients receiving subcutaneous injections of Centocor's golimumab (CNTO 148) 50mg and
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
23 June 2008
30 June 2008
19 June 2013
© 2013 thepharmaletter.com